or Try an Advanced Search...

    Technical Analysis for BMEA - Biomea Fusion, Inc.

    Grade Last Price % Change Price Change
    F 11.90 2.85% 0.33
    BMEA closed up 7.73 percent on Wednesday, May 1, 2024, on approximately normal volume.
    Earnings due: May 13
    *** please verify all earnings dates ***
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical BMEA trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 2.85%
    Wide Bands Range Expansion 2.85%
    Oversold Stochastic Weakness 2.85%
    MACD Bullish Signal Line Cross Bullish 10.80%
    Wide Bands Range Expansion 10.80%
    Oversold Stochastic Weakness 10.80%
    180 Bearish Setup Bearish Swing Setup 10.70%
    Wide Bands Range Expansion 10.70%
    Oversold Stochastic Weakness 10.70%
    Wide Bands Range Expansion 10.39%
    Older End-of-Day Signals for BMEA ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 2 hours ago
    Rose Above 20 DMA about 3 hours ago
    20 DMA Resistance about 3 hours ago
    Down 1% about 3 hours ago
    Up 2% about 3 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BMEA Chart by TradingView
    Basic chart:

    Profile

    Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer

    Is BMEA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 2 Biomea Fusion drops as JPMorgan downgrades on data for lead asset
    Apr 1 Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    Apr 1 Biomea Fusion GAAP EPS of -$0.98
    Apr 1 Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
    Apr 1 Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
    Mar 7 7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
    Mar 6 Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
    Mar 1 Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    Feb 27 Why Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology Research
    Feb 19 Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
    See more BMEA news...

    Comments

    T

    TraderMike about 1 year ago

    I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji).  These little biotechs are always interesting after having a big pop based on some good/promising news.  The standard plan seems to be to immediately issue a secondary offering -- which BMEA did.  So now I'm looking for it to climb back above that offering price of $30 and retest the March high.

    0 Reply
    View full discussion...

    Indicators

    Indicator Value
    52 Week High 43.64
    52 Week Low 8.125
    Average Volume 1,099,102
    200-Day Moving Average 14.82
    50-Day Moving Average 14.39
    20-Day Moving Average 11.73
    10-Day Moving Average 10.89
    Average True Range 0.96
    RSI (14) 42.53
    ADX 27.12
    +DI 19.24
    -DI 22.59
    Chandelier Exit (Long, 3 ATRs) 11.54
    Chandelier Exit (Short, 3 ATRs) 13.11
    Upper Bollinger Bands 13.58
    Lower Bollinger Band 9.88
    Percent B (%b) 0.46
    BandWidth 31.54
    MACD Line -1.04
    MACD Signal Line -1.14
    MACD Histogram 0.1056
    Fundamentals Value
    Market Cap 413.12 Million
    Num Shares 35.7 Million
    EPS -3.33
    Price-to-Earnings (P/E) Ratio -3.47
    Price-to-Sales 0.00
    Price-to-Book 3.18
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.79
    Resistance 3 (R3) 13.71 12.90 13.42
    Resistance 2 (R2) 12.90 12.33 12.94 13.30
    Resistance 1 (R1) 12.23 11.98 12.57 12.31 13.17
    Pivot Point 11.42 11.42 11.58 11.46 11.42
    Support 1 (S1) 10.75 10.85 11.09 10.83 9.97
    Support 2 (S2) 9.94 10.50 9.98 9.84
    Support 3 (S3) 9.27 9.94 9.72
    Support 4 (S4) 9.35